North America injectable drug delivery market is expected to reach USD 475,824.35 million by 2025 from USD 173,547.84 million in 2017, at a CAGR of 11.7% in the forecast period 2018 to 2025.


The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for North America injectable drug delivery market are listed below;

Baxter International, Inc.,
Becton Dickinson and Company,
Gerresheimer AG,
Pfizer, Inc.,
Schott AG,
Alkermes Plc.,
Eli Lilly and Company,
Sandoz,
Terumo Corporation,
Teva Pharmaceuticals Industries Ltd.
Ypsomed,
Bespak

The market is further segmented into;
Type
Usage Pattern
End-User
Mode of Administration
Distribution Channel
Application
Geography


The North America injectable drug delivery market is segmented on of type, portability, type, product type, application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.
The North America injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 67.3% market share in 2018, growing at a CAGR of 11.7% and will cross USD 321,636.51 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn?s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 51.3% market share in 2018, growing at a CAGR of 11.6% and will cross USD 243,167.7 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 12.7% in the forecast period, and is expected to reach USD 121,443.5 million in 2025 from USD 40,516.7 million in 2017.
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 91.7% market share in 2018, growing at a CAGR of 11.8% and will cross USD 440,541.8 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 43.2% market share in 2018, growing with highest CAGR of 12.3% and will cross USD 215,342.4 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 64.6% market share in 2018, growing at a CAGR of 11.7% and will cross USD 307,853.9 million by 2025. However, home healthcare settings companies segment is expected to grow at the highest CAGR of 12.3% in the forecast period, and is expected to reach USD 113,830.3 million in 2025 from USD 39,257.1 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 65.1% market share in 2018, growing the highest CAGR of 11.9% and will cross USD 315,277.4 million by 2025.
Based on geography, the North America injectable drug delivery market is segmented into geographical regions, such as
U.S.
Canada
Mexico

Covered in this report
The report covers the present scenario and the growth prospects of the North America injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst?s time when you purchase this market report. Details are provided within the report